[96a5a0]: / output / allTrials / identified / NCT00898573_identified.json

Download this file

314 lines (314 with data), 12.4 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
{
"info": {
"nct_id": "NCT00898573",
"official_title": "Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers",
"inclusion_criteria": "Healthy volunteers allowed",
"exclusion_criteria": "",
"miscellaneous_criteria": "DISEASE CHARACTERISTICS:\n\n* Pathologically confirmed invasive breast cancer\n\n * ErbB2-positive disease\n* Has received or is currently receiving lapatinib ditosylate\n\n * Documented clinical benefit while receiving lapatinib ditosylate (e.g., stable disease of ≥ 12 weeks duration OR a radiographic response)\n* Must have tumor tissue samples available for research studies\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* Not pregnant*\n* Coagulation profile normal*\n* Platelet count > 100,000/mm³* NOTE: *For patients requiring a post-treatment biopsy\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* Concurrent chemotherapy or trastuzumab (Herceptin®) allowed\n* No concurrent anticoagulants, including warfarin or low-molecular weight heparin*\n* No concurrent antiplatelet therapy, including aspirin, clopidogrel, or other antiplatelet agents* NOTE: *For patients requiring a post-treatment biopsy"
},
"inclusion_lines": [
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
}
],
"exclusion_lines": [],
"miscellaneous_lines": [
{
"line": "* Pathologically confirmed invasive breast cancer",
"criterions": [
{
"exact_snippets": "Pathologically confirmed invasive breast cancer",
"criterion": "invasive breast cancer",
"requirements": [
{
"requirement_type": "confirmation method",
"expected_value": "pathologically confirmed"
}
]
}
]
},
{
"line": "* ErbB2-positive disease",
"criterions": [
{
"exact_snippets": "ErbB2-positive disease",
"criterion": "ErbB2 status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "positive"
}
]
}
]
},
{
"line": "* Has received or is currently receiving lapatinib ditosylate",
"criterions": [
{
"exact_snippets": "Has received or is currently receiving lapatinib ditosylate",
"criterion": "lapatinib ditosylate treatment",
"requirements": [
{
"requirement_type": "status",
"expected_value": [
"received",
"currently receiving"
]
}
]
}
]
},
{
"line": "* Documented clinical benefit while receiving lapatinib ditosylate (e.g., stable disease of ≥ 12 weeks duration OR a radiographic response)",
"criterions": [
{
"exact_snippets": "Documented clinical benefit while receiving lapatinib ditosylate",
"criterion": "clinical benefit while receiving lapatinib ditosylate",
"requirements": [
{
"requirement_type": "documentation",
"expected_value": true
}
]
},
{
"exact_snippets": "stable disease of ≥ 12 weeks duration",
"criterion": "stable disease",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 12,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "radiographic response",
"criterion": "radiographic response",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Must have tumor tissue samples available for research studies",
"criterions": [
{
"exact_snippets": "tumor tissue samples available",
"criterion": "tumor tissue samples",
"requirements": [
{
"requirement_type": "availability",
"expected_value": true
}
]
}
]
},
{
"line": "* Hormone receptor status not specified",
"criterions": [
{
"exact_snippets": "Hormone receptor status",
"criterion": "hormone receptor status",
"requirements": [
{
"requirement_type": "specification",
"expected_value": false
}
]
}
]
},
{
"line": "* Menopausal status not specified",
"criterions": [
{
"exact_snippets": "Menopausal status",
"criterion": "menopausal status",
"requirements": [
{
"requirement_type": "specification",
"expected_value": false
}
]
}
]
},
{
"line": "* Not pregnant*",
"criterions": [
{
"exact_snippets": "Not pregnant",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "status",
"expected_value": false
}
]
}
]
},
{
"line": "* Coagulation profile normal*",
"criterions": [
{
"exact_snippets": "Coagulation profile normal",
"criterion": "coagulation profile",
"requirements": [
{
"requirement_type": "status",
"expected_value": "normal"
}
]
}
]
},
{
"line": "* Platelet count > 100,000/mm³* NOTE: *For patients requiring a post-treatment biopsy",
"criterions": [
{
"exact_snippets": "Platelet count > 100,000/mm³",
"criterion": "platelet count",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">",
"value": 100000,
"unit": "mm³"
}
}
]
}
]
},
{
"line": "PRIOR CONCURRENT THERAPY:",
"criterions": [
{
"exact_snippets": "PRIOR CONCURRENT THERAPY",
"criterion": "prior concurrent therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* See Disease Characteristics",
"criterions": [
{
"exact_snippets": "Disease Characteristics",
"criterion": "disease characteristics",
"requirements": [
{
"requirement_type": "N/A",
"expected_value": "See Disease Characteristics"
}
]
}
]
},
{
"line": "* Concurrent chemotherapy or trastuzumab (Herceptin®) allowed",
"criterions": [
{
"exact_snippets": "Concurrent chemotherapy ... allowed",
"criterion": "concurrent chemotherapy",
"requirements": [
{
"requirement_type": "allowance",
"expected_value": true
}
]
},
{
"exact_snippets": "Concurrent ... trastuzumab (Herceptin®) allowed",
"criterion": "concurrent trastuzumab (Herceptin®)",
"requirements": [
{
"requirement_type": "allowance",
"expected_value": true
}
]
}
]
},
{
"line": "* No concurrent anticoagulants, including warfarin or low-molecular weight heparin*",
"criterions": [
{
"exact_snippets": "No concurrent anticoagulants, including warfarin or low-molecular weight heparin",
"criterion": "concurrent anticoagulants",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
},
{
"requirement_type": "specific types",
"expected_value": [
"warfarin",
"low-molecular weight heparin"
]
}
]
}
]
},
{
"line": "* No concurrent antiplatelet therapy, including aspirin, clopidogrel, or other antiplatelet agents* NOTE: *For patients requiring a post-treatment biopsy",
"criterions": [
{
"exact_snippets": "No concurrent antiplatelet therapy, including aspirin, clopidogrel, or other antiplatelet agents",
"criterion": "concurrent antiplatelet therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
}
],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": [
{
"line": "DISEASE CHARACTERISTICS:",
"criterions": []
},
{
"line": "PATIENT CHARACTERISTICS:",
"criterions": []
}
]
}